Gossamer Bio 

€8.56
116
-€0.10-1.18% 14:32 Today

Statistics

Day High
8.76
Day Low
8.56
52W High
12.76
52W Low
0.108
Volume
-
Avg. Volume
-
Mkt Cap
52.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q2 2026
Next
-8.56
-6.83
-5.1
-3.37
Expected EPS
-3.37467512432
Actual EPS
N/A

Financials

-351.83%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
41.97MRevenue
-147.68MNet Income

Analyst Ratings

$47.67Average Price Target
The highest estimate is ⁦121.41⁩.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
0%
Sell
25%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4GB0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to Gossamer Bio's focus on immunology and oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the biotech space with a strong emphasis on immunology and inflammatory conditions, overlapping with Gossamer Bio's research areas.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a direct competitor in the biopharmaceutical field, particularly in areas like immunology and viral diseases, which are of interest to Gossamer Bio.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes with Gossamer Bio in the biotech industry, focusing on innovative therapeutics in areas such as oncology and cardiovascular disease.
Biogen
BIIB
Mkt Cap37.49B
Biogen is a competitor due to its focus on developing therapies for neurological and neurodegenerative diseases, a field that intersects with Gossamer Bio's interest in complex diseases.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes in the pharmaceutical and biotech sectors with a strong portfolio in immunology, oncology, and virology, areas Gossamer Bio is involved in.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is a competitor because of its extensive research and development in pharmaceuticals, including immunotherapy treatments that could compete with Gossamer Bio's products.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a global pharmaceutical company with a broad range of products that compete across several of Gossamer Bio's key areas of interest, including immunology and oncology.
Novartis
NVS
Mkt Cap303.67B
Novartis competes with Gossamer Bio in the pharmaceutical sector, particularly in research and development of innovative medicines in areas like autoimmunity, which overlaps with Gossamer's focus.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is a competitor because of its strong emphasis on the development of medicines in oncology, cardiovascular, renal, metabolism, and respiratory diseases, competing with Gossamer Bio's therapeutic areas.

About

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Show More
CEO
Faheem Hasnain
Employees
162
Country
United States
ISIN
US38341P2011
WKN
000A42M0V

Listings

0 Comments

Share your thoughts

FAQs

What is Gossamer Bio stock price today?▼
The current price of 4GB0.STU is €8.56 EUR — it has decreased by -1.18% in the past 24 hours. Watch Gossamer Bio stock price performance more closely on the chart.
What is Gossamer Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Gossamer Bio stocks are traded under the ticker 4GB0.STU.
What is Gossamer Bio market cap?▼
Today Gossamer Bio has the market capitalization of 52.36M
What is Gossamer Bio revenue for the last year?▼
Gossamer Bio revenue for the last year amounts to 41.97M EUR.
What is Gossamer Bio net income for the last year?▼
4GB0.STU net income for the last year is -147.68M EUR.
How many employees does Gossamer Bio have?▼
As of November 5, 2026, the company has 162 employees.
In which sector is Gossamer Bio located?▼
Gossamer Bio operates in the Health & Wellness sector.
When did Gossamer Bio complete a stock split?▼
The last stock split for Gossamer Bio was on September 11, 2026 with a ratio of 1:80.
Where is Gossamer Bio headquartered?▼
Gossamer Bio is headquartered in SAN DIEGO, United States.